Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene
- PMID: 7585510
Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene
Abstract
Clear cell renal carcinomas are most frequently characterized by loss of function of both copies of the von Hippel-Lindau (VHL) disease gene, suggesting that the VHL gene product plays an important role in regulating renal cell proliferation. To directly assess the function of the VHL gene product, we transfected the wild-type VHL gene into two renal carcinoma cell lines that lacked normal expression of the gene. Expression of the wild-type VHL gene led to a dramatic suppression of growth in two renal carcinoma cell lines, A498 and UMRC6 in vitro, as measured by colony formation and direct cell counting. Transfection of a naturally occurring mutant VHL gene (nucleotide 713 G to A, Arg to Gln) did not lead to growth suppression of these renal carcinoma cells, nor did transfection of the wild-type VHL gene into two non-renal tumor cell lines that expressed the endogenous wild-type VHL gene. Expression constructs, which included the first ATG at nucleotide 214, were sufficient to produce the strongest growth suppression. These experiments provide direct evidence that the VHL gene product functions to suppress the growth of renal carcinoma cells and also provide a model for mapping the domains of the VHL protein important in suppressing tumor growth.
Similar articles
-
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.Cancer Res. 1994 Jun 1;54(11):2852-5. Cancer Res. 1994. PMID: 8187067
-
Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene.Oncogene. 1995 Jun 1;10(11):2185-94. Oncogene. 1995. PMID: 7784063
-
Mutations of the VHL tumour suppressor gene in renal carcinoma.Nat Genet. 1994 May;7(1):85-90. doi: 10.1038/ng0594-85. Nat Genet. 1994. PMID: 7915601
-
Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer.JAMA. 1995 Feb 15;273(7):564-70. JAMA. 1995. PMID: 7837390 Review. No abstract available.
-
Von Hippel-Lindau disease-associated renal cell carcinoma: a call to action.Curr Opin Urol. 2022 Jan 1;32(1):31-39. doi: 10.1097/MOU.0000000000000950. Curr Opin Urol. 2022. PMID: 34783716 Review.
Cited by
-
Immune and genetic therapies for advanced renal cell carcinoma.Rev Urol. 2000 Winter;2(1):54-60. Rev Urol. 2000. PMID: 16985736 Free PMC article.
-
PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.Cancer Biol Ther. 2009 Jul;8(14):1389-401. doi: 10.4161/cbt.8.14.8880. Epub 2009 Jul 30. Cancer Biol Ther. 2009. PMID: 19483472 Free PMC article.
-
Gene therapy for urologic cancer.Curr Urol Rep. 2002 Feb;3(1):75-81. doi: 10.1007/s11934-002-0014-7. Curr Urol Rep. 2002. PMID: 12084223 Review.
-
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma.Ther Adv Urol. 2015 Oct;7(5):286-94. doi: 10.1177/1756287215591764. Ther Adv Urol. 2015. PMID: 26425143 Free PMC article. Review.
-
VHL and PTEN loss coordinate to promote mouse liver vascular lesions.Angiogenesis. 2010 Mar;13(1):59-69. doi: 10.1007/s10456-010-9164-2. Epub 2010 Mar 11. Angiogenesis. 2010. PMID: 20221685 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical